OncoFirm-CEA Rapid Test

Description

OncoFirm-CEA Rapid Test for Carcinoembryonic Antigen (CEA) – Colorectal, Breast, Lung, and Pancreatic Cancer Screening

Overview:

OncoFirm-CEA is a rapid diagnostic test developed by OncoFirm Diagnostics for the detection and monitoring of Carcinoembryonic Antigen (CEA), a well-established biomarker associated with colorectal cancer and other solid tumors, including breast, lung, and pancreatic cancers. Built on our advanced lateral flow assay (LFA) platform, OncoScreen-CEA delivers accurate, lab-quality results in under 15 minutes, enabling timely and accessible cancer screening at the point of care.

• Front Panel (Main Messaging)
• OncoFirm Diagnostics
• Early Rapid Cancer Screening Test
• Detect Early. Save Lives.
• Fast & Reliable Results
• Easy-to-Use Lateral Flow Cassette
• For Professional Use / Point-of-Care Settings

Side Panel (Product Highlights or Benefits)

• Results in <15 minutes
• High-sensitivity cancer biomarkers
• No lab equipment required
• Supports early intervention and treatment planning
• Back Panel (Instructions/Compliance)

Intended Use:

This test is designed for the qualitative detection of tumor-associated biomarkers in human serum or whole blood. For use by healthcare professionals.

Storage: Store at 2–30°C. Do not freeze.

Regulatory: CE-IVDR Pending | FDA 510(k) Submission in Progress

Manufactured by: OncoFirm Diagnostics Corporation

[131 Continental Dr, Suite 305, City of Newark, County of New Castle, Delaware 19713] | [www.OncoFirm.com] | [info@oncofirm.com]

https://oncofirmdiagnostics.com/oncoscreen-cea-2